Castle Biosciences Inc
CSTL- Exchange
- Nasdaq
- Industry
- Services-Medical Laboratories
- SEC CIK
- 0001447362
In the last 90 days, Castle Biosciences Inc insiders filed 0 open-market purchases and 20 sales; 176 institutions reported holding it in 13F filings for Q2 2026, worth $653.8M in total; no superinvestor holds it.
- Currency
- USD
- Source
- SEC XBRL data (10-K, 10-Q, 20-F, 40-F)
- Updated
- Nov 8, 2026, 10:49 PM ET
Revenue flow, FY2025
Where the revenue went in FY2025, from the income statement below. Green is profit; orange is costs, expenses and taxes. Percentages are shares of revenue; hover over a band or a bar for the exact amount.
Net loss for FY2025: $24.2M (7.0% of revenue).
Income statement
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 13, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Revenue | $344.2M | $332.1M | $219.8M | $137.0M | $94.1M |
| Cost of revenue | $71.0M | $60.2M | $45.0M | $32.0M | $15.8M |
| Research and development | $51.9M | $52.0M | $53.6M | $44.9M | $29.6M |
| Selling, general and administrative | $229.3M | $200.0M | $180.2M | $143.0M | $86.7M |
| Operating income | -$42.8M | $8.67M | -$68.0M | -$72.9M | -$40.1M |
| Interest expense | – | – | $11.0K | $17.0K | $1.00K |
| Income tax | -$5.36M | $3.32M | $101.0K | -$1.77M | -$8.72M |
| Net income | -$24.2M | $18.2M | -$57.5M | -$67.1M | -$31.3M |
| EPS, basic | $-0.83 | $0.66 | $-2.14 | $-2.58 | $-1.24 |
| EPS, diluted | $-0.83 | $0.62 | $-2.14 | $-2.58 | $-1.24 |
| Weighted shares, basic | 29.0M | 27.8M | 26.8M | 26.1M | 25.1M |
| Weighted shares, diluted | 29.0M | 29.3M | 26.8M | 26.1M | 25.1M |
| Margins and growth | |||||
| Operating margin | -12.4% | 2.6% | -30.9% | -53.2% | -42.6% |
| Net margin | -7.0% | 5.5% | -26.1% | -49.0% | -33.3% |
| Revenue growth, year over year | +3.7% | +51.1% | +60.4% | +45.7% | +50.2% |
| Net income growth, year over year | −232.4% | – | – | – | – |
Balance sheet
Each column is one fiscal year, newest first.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 13, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Cash and equivalents | $116.7M | $119.7M | $98.8M | $122.9M | $329.6M |
| Short-term investments | $182.8M | $173.4M | – | – | – |
| Accounts receivable | $43.4M | $51.2M | $38.3M | $23.5M | $17.3M |
| Inventory | $10.3M | $8.13M | $7.94M | $3.98M | $2.02M |
| Total current assets | $361.1M | $360.2M | $295.6M | $292.3M | $353.7M |
| Property, plant and equipment | – | – | – | $14.3M | – |
| Goodwill | $10.7M | $10.7M | $10.7M | $10.7M | – |
| Intangible assets | $88.9M | $95.5M | $106.6M | $115.7M | $88.9M |
| Total assets | $578.6M | $531.2M | $453.3M | $447.3M | $462.6M |
| Accounts payable | $18.7M | $6.90M | $10.3M | $4.73M | $2.55M |
| Short-term debt | $417.0K | $278.0K | – | – | – |
| Total current liabilities | $68.7M | $49.4M | $47.7M | $36.1M | $24.9M |
| Long-term debt | $9.64M | $9.74M | – | – | – |
| Total liabilities | $107.7M | $75.4M | $62.1M | $48.2M | $50.8M |
| Shareholders' equity | $470.9M | $455.8M | $391.3M | $399.1M | $411.7M |
Cash flow statement
Each column is one fiscal year, newest first. Free cash flow is operating cash flow minus capital expenditures.
| Line item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Period end | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 |
| Filing | 10-K | 10-K | 10-K | 10-K | 10-K |
| Reported | Jan 13, 2026 | Jan 13, 2025 | Jan 8, 2024 | Jan 9, 2023 | Jan 10, 2022 |
| Operating cash flow | $64.3M | $64.9M | -$5.63M | -$41.7M | -$19.0M |
| Capital expenditures | $36.0M | $28.3M | $13.6M | $5.63M | $3.48M |
| Free cash flow | $28.3M | $36.5M | -$19.2M | -$47.3M | -$22.5M |
| Depreciation and amortization | $40.8M | $16.0M | $12.3M | $10.5M | $3.41M |
| Stock-based compensation | $45.9M | $50.3M | $51.2M | $36.3M | $21.7M |
| Investing cash flow | -$60.4M | -$50.1M | -$16.2M | -$166.5M | -$66.7M |
| Financing cash flow | -$6.96M | $6.14M | -$2.30M | $1.51M | $5.42M |
| Net change in cash | -$2.98M | $20.9M | -$24.1M | -$206.7M | -$80.2M |
| Ratio | |||||
| Stock-based compensation, % of revenue | 13.3% | 15.2% | 23.3% | 26.5% | 23.1% |
Shares outstanding
Common shares outstanding as stated on the cover of each 10-K and 10-Q. The date is the cover date, not the period end; a rising count means dilution.
| Cover date | Shares outstanding | Change in a year | Filing |
|---|---|---|---|
| Oct 29, 2026 | 30.8M | +5.6% | SEC |
| Jul 23, 2026 | 30.5M | +5.3% | SEC |
| Apr 29, 2026 | 30.3M | +5.0% | SEC |
| Feb 19, 2026 | 29.7M | +4.3% | SEC |
| Oct 27, 2025 | 29.2M | +4.2% | SEC |
| Jul 28, 2025 | 29.0M | +4.6% | SEC |
| Apr 24, 2025 | 28.9M | +4.6% | SEC |
| Feb 20, 2025 | 28.5M | +3.9% | SEC |
Notes and known gaps
How these numbers are put together, and what they can't tell you.
- Numbers come from the XBRL data in each period's original 10-K, 10-Q, 20-F or 40-F, or its amendment. They are shown as filed: later filings don't restate earlier periods here.
- Reported is the filing date of the first 8-K with Item 2.02 (results of operations) after the period ended, no later than the 10-Q or 10-K and within 120 days. Companies that release results only in the 10-Q, and foreign companies, which use Form 6-K, have none.
Known gaps
- Foreign companies that file Form 20-F or 40-F have annual statements only: their quarterly results are furnished on Form 6-K, which has no XBRL data.
- EPS and share counts are as reported at the time, not adjusted for later stock splits.
- For ADRs, EPS is per ordinary share, not per ADS (one TSMC ADS is five ordinary shares).
- For banks, revenue may be interest income only, depending on how the bank tags its filings; cost of revenue and gross profit are usually blank.
- Companies with several share classes, such as Berkshire Hathaway, may have no EPS and no cover share count.
- Depreciation and amortization is missing for some companies that report it under their own XBRL tags.